Evidence map›Paper›PMID 30067426›Full record

ArticleCancer biology & therapy2018

iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma.

Kun Wang, Zhen Chen, Lu Long, Ya Tao, Qiong Wu, Manlin Xiang, Yunlai Liang, Xulin Xie, Yuan Jiang, Zhiqiang Xiao and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kun Wanga Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Zhen Chena Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Lu Longa Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Ya Taoa Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Qiong Wua Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Manlin Xianga Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Yunlai Lianga Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Xulin Xiea Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Yuan Jianga Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Zhiqiang Xiaoc The Higher Educational Key Laboratory for Cancer Proteomics and Translational Medicine of Hunan Province , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Yahui Yand Department of pathology , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Shiyang Qiua Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Bin Yia Department of Clinical Laboratory , Xiangya Hospital, Central South University , Changsha , Hunan Province , China.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is a highly prevalent disease in Southeast Asia. The disease is typically diagnosed in the later stages, and chemotherapy resistance often causes treatment failure. To investigate the underlying mechanisms of drug resistance, we searched for chemoresistant-associated proteins in NPC and drug-resistant NPC cell lines using isobaric tags for relative and absolute quantitation combined with nano liquid chromatography-tandem mass spectrometry. The chemoresistant NPC cell lines CNE1DDP and CNE2DDP were resistant to 1 mg/L cisplatin, had resistant indexes of 4.58 and 2.63, respectively, and clearly grew more slowly than the NPC cell lines CNE1 and CNE2. Using three technical replicates, we identified 690 nonredundant proteins, 56 of which were differentially expressed in both groups of cell lines (CNE1 vs. CNE1DDP and CNE2 vs. CNE2DDP). Gene Ontology, KEGG pathway, and miRNA analyses and protein-protein interactions of differentially expressed proteins showed that proteins TRIM29, HSPB1, CLIC1, ANXA1, and STMN1, among others, may play a role in the mechanisms of chemoresistance in clinical therapy. The chemotherapy-resistant proteomic profiles obtained may allow the identification of novel biomarkers for early detection of chemoresistance in NPC and other cancers.

Indexed as

Gene Expression Regulation, NeoplasticProteomeProteomicsBiomarkers, TumorCell Line, TumorCell SurvivalComputational BiologyDrug Resistance, NeoplasmGene OntologyHumansInhibitory Concentration 50Nasopharyngeal NeoplasmsProtein Interaction MappingProtein Interaction MapsQuantitative Structure-Activity RelationshipTandem Mass SpectrometryBiomarkers, TumorProteomeANXA1bioinformaticschemoresistanceiTRAQnasopharyngeal carcinomaproteomic profilesTRIM29

Identifiers

PMID30067426
PMCPMC6154836
OpenAlexW2885417931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.